MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2.


Journal

Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063

Informations de publication

Date de publication:
12 2019
Historique:
pmc-release: 05 03 2020
entrez: 7 3 2019
pubmed: 7 3 2019
medline: 21 8 2019
Statut: ppublish

Résumé

This study is aimed to elucidate the mechanisms underlying the role of miR-485-5p in small cell lung cancer (SCLC). The expression of miR-485-5p were quantified with real time quantitative PCR and it was found that the level of miR-485-5p was lower in SCLC tissues than normal tissues. In cultured SCLC cell lines, overexpression of miR-485-5p reduced cell proliferation, migration, and invasion in vitro, whereas knockdown of miR-485-5p performed contrary. FLOT2 expression was obviously upregulated and negatively correlated with miR-485-5p expression level in SCLC tissues. Overexpression of miR-485-5p significantly inhibited the protein expression of flotillin-2 (FLOT2) in cultured SCLC cells. Luciferase reporter assay confirmed that FLOT2 was a direct target of miR-485-5p in SCLC cells. It is concluded that miR-485-5p, as a tumor suppressor, inhibits the growth and metastasis in SCLC by targeting FLOT2. Upregulation of miR-485-5p expression may be an attractive strategy for SCLC therapy.

Identifiants

pubmed: 30836864
doi: 10.1080/21655979.2019.1586056
pmc: PMC6527069
doi:

Substances chimiques

3' Untranslated Regions 0
Antagomirs 0
MIRN485 microRNA, human 0
Membrane Proteins 0
MicroRNAs 0
Oligoribonucleotides 0
flotillins 0
Luciferases EC 1.13.12.-

Types de publication

Journal Article

Langues

eng

Pagination

1-12

Références

Curr Biol. 2003 Apr 15;13(8):686-90
pubmed: 12699627
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Cell Mol Life Sci. 2005 Oct;62(19-20):2228-40
pubmed: 16091845
Genes Dev. 2006 Mar 1;20(5):515-24
pubmed: 16510870
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Biochem J. 2007 Apr 15;403(2):313-22
pubmed: 17206938
Curr Biol. 2007 Jul 3;17(13):1151-6
pubmed: 17600709
J Cell Sci. 2009 Apr 1;122(Pt 7):912-8
pubmed: 19258392
J Cell Biol. 2010 Nov 15;191(4):771-81
pubmed: 21059848
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):551-6
pubmed: 21187433
Toxicol Appl Pharmacol. 2012 Mar 15;259(3):311-9
pubmed: 22289360
Saudi Med J. 2012 May;33(5):508-14
pubmed: 22588811
Plant Cell. 2012 May;24(5):2105-22
pubmed: 22589463
Drug Discov Today. 2013 Mar;18(5-6):282-9
pubmed: 23064097
Hepatology. 2013 Feb;57(2):840-7
pubmed: 23081718
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19397-402
pubmed: 23132946
Curr Med Chem. 2013;20(1):4-21
pubmed: 23150999
Nat Rev Clin Oncol. 2013 Apr;10(4):235-44
pubmed: 23438759
Curr Opin Genet Dev. 2013 Feb;23(1):3-11
pubmed: 23465882
Clin Cancer Res. 2013 Oct 15;19(20):5602-12
pubmed: 23995857
J Thorac Dis. 2013 Sep;5 Suppl 4:S440-5
pubmed: 24102018
OMICS. 2014 Jan;18(1):54-64
pubmed: 24237355
JAMA. 2014 Apr 9;311(14):1430-7
pubmed: 24715074
Cancer Sci. 2014 Jul;105(7):755-62
pubmed: 24815002
Tumour Biol. 2014 Dec;35(12):12743-8
pubmed: 25227664
Cell Physiol Biochem. 2015;35(1):184-90
pubmed: 25591761
Oncotarget. 2015 May 20;6(14):12543-57
pubmed: 26002553
Cell Physiol Biochem. 2015;36(3):1186-96
pubmed: 26111756
Cell Physiol Biochem. 2015;36(3):1026-36
pubmed: 26112332
Sci Rep. 2015 Jul 24;5:11614
pubmed: 26206082
Biosci Rep. 2017 Mar 15;37(2):
pubmed: 28188157
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):224-230
pubmed: 28503944
Am J Transl Res. 2017 Jul 15;9(7):3336-3344
pubmed: 28804551
Medicine (Baltimore). 2017 Oct;96(42):e8176
pubmed: 29049199
Oncotarget. 2017 Jul 26;8(41):70084-70096
pubmed: 29050263
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
Life Sci. 2018 Apr 15;199:104-111
pubmed: 29510198

Auteurs

Feng Gao (F)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Hao Wu (H)

b Department of Clinical Laboratory , Hebei Medical University , Shijiazhuang , China.

Rui Wang (R)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Yang Guo (Y)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Zefeng Zhang (Z)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Tao Wang (T)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Guoliang Zhang (G)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Changjiang Liu (C)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Junfeng Liu (J)

a Department of Thoracic Surgery , the Fourth Hospital of Hebei Medical University , Shijiazhuang , China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH